Board of Directors

Srini Akkaraju, M.D., Ph.D.

Managing Director, New Leaf Venture Partners

Srini Akkaraju is a Managing Director of New Leaf Venture Partners and concentrates on biopharmaceuticals investments.  Srini joined New Leaf in January 2009.  Prior to joining New Leaf, Srini was a co-founder and Managing Director at Panorama Capital.  Before forming Panorama, Srini served as Partner of J.P. Morgan Partners, where he was responsible for leading venture investing in biotech companies.  Earlier, Srini held business and corporate development positions at Genentech.  During his tenure at Genentech, Srini was responsible for worldwide partnering activities, in-licensing of therapeutics and out-licensing of development projects.  In addition, he also was a founding member of BioStreet, an online marketplace for biotech opportunities.  Srini is the author of a number of peer-reviewed articles, including ones published in Science and Nature.  He received B.A. degrees in both Biochemistry and Computer Science from Rice University and M.D. and Ph.D. degrees in Immunology from Stanford University School of Medicine.

Felix J. Baker, Ph.D. – Chairman of the Board

Managing Partner, Baker Brothers Investments

Felix J. Baker, Ph.D. has served as a director of Trimeris since April 2004, a director of Synageva since October 2000, and Chairman of the Board of Synageva since 2003.  Dr. Baker is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Mr. Julian Baker, founded in 2000.  Dr. Baker’s firm manages Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies.  Dr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family.  Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.  In addition to Synageva and Trimeris, Dr. Baker is a director of Ardea Bioscience, Inc. and Seattle Genetics, Inc., both of which are publicly traded biotechnology companies.  Dr. Baker was previously a director of AnorMED Inc., Conjuchem Inc. and Neurogen Corporation, which were publicly traded companies during Dr. Baker’s service.

---

Stephen R. Biggar, M.D., Ph.D.

Partner, Baker Brothers Investments

Stephen R. Biggar, M.D., Ph.D. has served as a director of Synageva since May 2004.  Since October 2006, Dr. Biggar has served as a Partner at Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies.  From April 2002 to October 2006, he served as Principal with Baker Brothers Investments which he had joined as an Associate in April 2000.  Prior to joining Baker Brothers, Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. degree in Genetics from the University of Rochester.  Dr. Biggar also serves as a director for BioCryst Pharmaceuticals, Inc., a publicly traded biotechnology company.

---

Stephen R. Davis

Thomas R. Malley

Former Portfolio Manager, Janus Global Life Sciences Fund

Thomas R. Malley joined Synageva’s board of directors in October 2006.  Since May 2007, Mr. Malley has served as President of Mossrock Capital, LLC, a private investment firm.  From December 1998 to May 2007, Mr. Malley served with Janus Mutual Funds, including as Vice President and Portfolio Manager for the Janus Global Life Sciences Fund. From April 1991 to December 1998, Mr. Malley served as an equity analyst for Janus Mutual Funds.  Mr. Malley previously served as a director of Cougar Biotechnology, Inc. from 2007-2009, which was a publicly traded company until Johnson & Johnson acquired the company in 2009.  Mr. Malley holds a B.S. in Biology from Stanford University.

---

Sanj K. Patel

President & Chief Executive Officer, Synageva

Sanj K. Patel was appointed President and Chief Executive Officer and elected as a director of Synageva in June 2008. He created the vision and strategy for Synageva, launching its focus on rare diseases and raising more than $100 million in capital including taking the company public on the NASDAQ Global Market in November 2011. Sanj has more than 20 years of experience in the pharmaceutical and biotech industries and brings a combination of scientific, clinical operations and business skills to Synageva. He joined Synageva from Genzyme Corporation (1999-2008) where most recently he was the head of U.S. Sales, Marketing and Commercial Operations for Genzyme Therapeutics’ Lysosomal Storage Disorder franchise and led the U.S. launch of Myozyme in addition to sales and marketing responsibility for Cerezyme, Fabrazyme and Aldurazyme. Previously, Sanj held several cross-functional senior leadership roles at Genzyme, including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council. He was responsible for clinical operations and development for all cross-business Genzyme products and was instrumental in the path to commercialization for several treatments. Notably, Sanj led the Fabrazyme clinical operations team and development program to FDA approval in April 2003. Prior to Genzyme, Sanj held roles in clinical research and commercial development with increasing levels of responsibility at Burroughs Wellcome, Hoechst Marrion Roussel and Fujisawa Pharmaceuticals. Sanj obtained his BSc with Honors in Pure and Applied Biology (Biotechnology) from the University of the South Bank, London. He completed his post-graduate management and business degree, and doctorate level research program in clinical pharmacology, at Ealing College, London, King’s College and the Wellcome Foundation, respectively.

Barry Quart, Pharm.D.

President and Chief Executive Officer, Ardea Biosciences, Inc.

Barry Quart, Pharm.D. previously served as a director of Trimeris since June 2007 and as a director of Synageva since November 2011. Since December 2006, Dr. Quart has served as President and Chief Executive Officer of Ardea Biosciences, Inc. He has also been a director of Ardea since December 2006. From 2002 until December 2006, Dr. Quart was President of Napo Pharmaceuticals, Inc. Dr. Quart was also a director of Napo from April 2002 to December 2006. Prior to Napo, Dr. Quart was Senior Vice President, Pfizer Global Research and Development and the Director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, since 1999. Prior to joining Agouron in 1993, Dr. Quart spent over 10 years at Bristol-Myers Squibb in both Clinical Research and Regulatory Affairs. Dr. Quart holds a Pharm.D. from the University of California, San Francisco.

Robyn Samuels

Vice President, Tisch Family Interests

Robyn Samuels has served as a director of Synageva since April 2009.  Ms. Samuels is currently Vice President at TFMG Associates, LLC, the family office for the Laurence A. Tisch and Preston Robert Tisch families.  She has served in this capacity since 1996 and is responsible for a wide range of investment activities including public and private equity, real estate, and other transactions.  Prior to joining TFMG Associates, she was a financial analyst in the investment banking division of Goldman, Sachs & Co.  Robyn received an A.B. in Economics from Barnard College and an M.B.A. from Harvard Business School.